SUNDAY, JULY 23, 2017

Visterra receives contract to develop new treatment for influenza A

Visterra receives contract to develop new treatment for influenza A | Courtesy of
Visterra, Inc. has recently received a contract worth up to $204.5 million to further develop its new monoclonal antibody to treat influenza A.

Visterra, Inc. is a clinical-stage biotechnology company that identifies unique disease targets and creates therapeutics for infectious diseases with its proprietary technology platform.

The contract was provided by the Biomedical Advanced Research and Development Authority (BARDA). The funds will last for five years and will apply specifically to the new treatment, called VIS410.

“We are pleased that BARDA has awarded this contract covering the development of VIS410,” Brian Pereira, MD, President and Chief Executive Officer of Visterra, said.

The contract finances clinical trials, pre-clinical toxicology studies, optimized manufacturing processes, and materials for clinical trials, as well as any other related regulatory activities that will further develop VIS410.

“Visterra is proud to play an important role in addressing the significant public health concern of seasonal influenza A and the growing threat of emerging strains of influenza A," Pereira said. "This award from BARDA will support the continued development of VIS410, our lead product candidate, which was designed and engineered using our proprietary technology platform.”

Influenza A is seasonal but has the potential to become pandemic which has led to attempts to develop effective treatments for the illness. 

Organizations in this story

Visterra Inc One Kendall Square, Cambridge, MA 02139, United States Cambridge, MA 02139

Get notified the next time we write about Visterra Inc!